This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Poniard Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript

Poniard Pharmaceuticals, Inc. ( PARD)

Q3 2010 Earnings Call

November 9, 2010 4:30 PM ET

Executives

Susan Neath – Investor Relations

Ronald Martell – Chief Executive Officer

Mike Jackson – Interim Chief Financial Officer

Dr. Michael Perry – President and Chief Medical Officer

Analysts

Simos Simeonidis – Rodman & Renshaw

Presentation

Operator

Good day. And welcome to the Poniard Pharmaceuticals [Second] Quarter 2010 Earnings Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Susan Neath. Please go ahead, Susan.

Susan Neath

Good afternoon. And thank you for joining us. Poniard issued a press release today, which is available on the company’s website at www.poniard.com. Comments made on this call will contain forward-looking statements relating to, among other things, the commercial potential of the company’s picoplatin and product candidates, the company’s corporate strategies and objectives, regulatory and partnering efforts, product development activity, clinical and regulatory goals, financial condition, future expectations and prospects.

Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of important factors, risks and uncertainties, including the company’s anticipated future operating losses, future capital requirements and ability to obtain future funding, the risks that strategic transactions may not be established on a timely basis on terms that are ultimately favorable to the company or at all, the potential safety, efficacy, and commercial viability of picoplatin, the risk that the company’s additional analysis of data from clinical trials of picoplatin may produce negative or inclusive results, or may be inconsistent with previously announced results or previously conducted trials, the company’s ability to retain key personnel, competition from third parties, the company’s ability to preserve and protect intellectual property rights, the company’s dependence on third-party manufacturers, suppliers, and other contractors, changes in technology, government regulation, and general market conditions, the receipt and timing of FDA and other required regulatory approval, and the other risks and uncertainties described in the company’s reports filed with the Securities and Exchange Commission, including the company’s annual report on Form 10-K for the year ended December 31, 2009, and the company’s Form 10-Q for the quarter ended September 30, 2010.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs